Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026
Coherus Oncology announced it will disclose interim clinical data for tagmokitug, its cytolytic anti-CCR8 antibody, on October 28, 2026, with a management webcast from 4:30 to 6:00 p.m. ET. The data cover tagmokitug in combination with LOQTORZI (toripalimab) across multiple solid tumors; tagmokitug is in Phase 1b/2a studies in head and neck, colorectal, gastric and esophageal cancers. Key opinion leaders have been invited to the webcast, which will be archived on the company's investor site.
Key figures
- Drug Name
- tagmokitug (anti-CCR8 antibody)
- Phase Of Trial
- Phase 1b/2a
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.